CA2054686C - Treatment of polycystic ovarian disease - Google Patents

Treatment of polycystic ovarian disease Download PDF

Info

Publication number
CA2054686C
CA2054686C CA 2054686 CA2054686A CA2054686C CA 2054686 C CA2054686 C CA 2054686C CA 2054686 CA2054686 CA 2054686 CA 2054686 A CA2054686 A CA 2054686A CA 2054686 C CA2054686 C CA 2054686C
Authority
CA
Canada
Prior art keywords
gonadotropin
lhrh
use according
releasing hormone
phe2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2054686
Other languages
English (en)
French (fr)
Other versions
CA2054686A1 (en
Inventor
Bruno Lunenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909005958A external-priority patent/GB9005958D0/en
Priority claimed from GB909011823A external-priority patent/GB9011823D0/en
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of CA2054686A1 publication Critical patent/CA2054686A1/en
Application granted granted Critical
Publication of CA2054686C publication Critical patent/CA2054686C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA 2054686 1990-03-16 1991-03-14 Treatment of polycystic ovarian disease Expired - Fee Related CA2054686C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9005958.5 1990-03-16
GB909005958A GB9005958D0 (en) 1990-03-16 1990-03-16 Treatment of polycystic ovarian disease
GB9011823.3 1990-05-25
GB909011823A GB9011823D0 (en) 1990-05-25 1990-05-25 Treatment of polycystic ovarian disease
PCT/EP1991/000479 WO1991014704A2 (en) 1990-03-16 1991-03-14 Treatment of polycystic ovarian disease

Publications (2)

Publication Number Publication Date
CA2054686A1 CA2054686A1 (en) 1991-09-17
CA2054686C true CA2054686C (en) 2007-09-25

Family

ID=26296796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2054686 Expired - Fee Related CA2054686C (en) 1990-03-16 1991-03-14 Treatment of polycystic ovarian disease

Country Status (11)

Country Link
EP (1) EP0472725B1 (de)
JP (1) JP3112172B2 (de)
AT (1) ATE153345T1 (de)
AU (1) AU647138B2 (de)
CA (1) CA2054686C (de)
DE (1) DE69126180T2 (de)
DK (1) DK0472725T3 (de)
ES (1) ES2102397T3 (de)
GR (1) GR3024225T3 (de)
IL (1) IL97571A (de)
WO (1) WO1991014704A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492177B1 (en) * 1990-03-16 2002-12-10 Applied Research Systems Ars Holding Nv Kit for use in treatment of polycystic ovarian disease
US6489288B1 (en) * 1990-03-16 2002-12-03 Applied Research Systems Ars Holding Treatment of polycystic ovarian disease
FI94181C (fi) * 1992-06-29 1995-07-25 Medix Biochemica Ab Oy Diagnostinen menetelmä synnytysajankohdan ennustamiseksi sekä siihen käytettävä reagenssipakkaus
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK272789D0 (da) * 1989-06-02 1989-06-02 Novo Nordisk As Fremgangsmaade og praeparat til behandling af infertilitet

Also Published As

Publication number Publication date
CA2054686A1 (en) 1991-09-17
IL97571A0 (en) 1992-06-21
ES2102397T3 (es) 1997-08-01
IL97571A (en) 1999-11-30
WO1991014704A3 (en) 1991-11-14
DE69126180T2 (de) 1997-08-28
ATE153345T1 (de) 1997-06-15
JP3112172B2 (ja) 2000-11-27
EP0472725B1 (de) 1997-05-21
WO1991014704A2 (en) 1991-10-03
AU7879791A (en) 1991-10-21
GR3024225T3 (en) 1997-10-31
DE69126180D1 (de) 1997-06-26
JPH05501119A (ja) 1993-03-04
AU647138B2 (en) 1994-03-17
DK0472725T3 (da) 1997-11-03
EP0472725A1 (de) 1992-03-04

Similar Documents

Publication Publication Date Title
Quaas et al. Pharmacology of medications used for ovarian stimulation
Shobokshi et al. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy
US7405197B2 (en) Use of hCG in controlled ovarian hyperstimulation
Zafeiriou et al. The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction
CA2054686C (en) Treatment of polycystic ovarian disease
EP1425033B1 (de) Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke
TAPANAINEN et al. Short and long term effects of growth hormone on circulating levels of insulin-like growth factor-I (IGF-I), IGF-binding protein-1, and insulin: A placebo controlled study
US6489288B1 (en) Treatment of polycystic ovarian disease
HRP20040070A2 (en) Use of lh in controlled ovarian hyperstimulation
US6492177B1 (en) Kit for use in treatment of polycystic ovarian disease
Kenigsberg et al. Induction of ovulation in primate models
Giustina et al. Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women
Siler-Khodr et al. Dose-related actions of GnRH II analog in the cycling rhesus monkey
Akagbosu The use of GnRH agonists and antagonists in infertility
Shoham et al. Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs, and recombinant gonadotropins
Akagbosu et al. The use of gonadotropin releasing hormone agonists and antagonists in infertility
Thomas et al. Pharmacology of adenohypophyseal hormones
Venturini et al. Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease: a new approach to induction of ovulation
Lissak et al. The effect of metoclopramide on ovarian responsiveness to gonadotropin administration in patients with severe polycystic ovarian syndrome
Fraser Risk of luteal phase inadequacy after GnRH agonist-induced ovulation
Baird Manipulation of the ovarian cycle
Cataldo Role of non-gonadotropin hormones
AU2002324183A1 (en) Use of hCG and LH in controlled ovarian hyperstimulation
AU2002324179A1 (en) Use of hCG in controlled ovarian hyperstimulation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed